bluebird bio, Inc.

NasdaqGS:BLUE Stock Report

Market Cap: US$186.3m

bluebird bio Valuation

Is BLUE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BLUE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BLUE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BLUE's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BLUE?

Other financial metrics that can be useful for relative valuation.

BLUE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue14.5x
Enterprise Value/EBITDA-2.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BLUE's PS Ratio compare to its peers?

The above table shows the PS ratio for BLUE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.6x
PBYI Puma Biotechnology
0.9x-1.9%US$193.0m
TLSI TriSalus Life Sciences
9.6x30.2%US$202.3m
RIGL Rigel Pharmaceuticals
1.4x17.4%US$159.2m
CRVO CervoMed
18.6x40.4%US$154.3m
BLUE bluebird bio
8.3x40.1%US$186.3m

Price-To-Sales vs Peers: BLUE is expensive based on its Price-To-Sales Ratio (8.3x) compared to the peer average (7.6x).


Price to Earnings Ratio vs Industry

How does BLUE's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.0%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.0%
n/an/an/a
No more companies

Price-To-Sales vs Industry: BLUE is good value based on its Price-To-Sales Ratio (8.3x) compared to the US Biotechs industry average (11.6x).


Price to Sales Ratio vs Fair Ratio

What is BLUE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLUE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BLUE's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BLUE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.94
US$4.06
+332.0%
60.3%US$8.00US$1.00n/a12
May ’25US$0.91
US$4.06
+346.7%
60.3%US$8.00US$1.00n/a12
Apr ’25US$1.24
US$4.23
+241.0%
59.3%US$8.00US$1.00n/a12
Mar ’25US$1.57
US$4.76
+203.9%
38.3%US$8.00US$2.00n/a11
Feb ’25US$1.00
US$4.76
+376.2%
38.3%US$8.00US$2.00n/a11
Jan ’25US$1.38
US$4.63
+235.6%
37.9%US$8.00US$2.00n/a10
Dec ’24US$4.26
US$7.20
+69.1%
40.3%US$13.00US$3.00n/a12
Nov ’24US$2.94
US$7.10
+141.5%
34.4%US$11.00US$3.00n/a12
Oct ’24US$3.04
US$7.10
+133.6%
34.4%US$11.00US$3.00n/a12
Sep ’24US$3.90
US$7.36
+88.8%
32.4%US$11.00US$3.00n/a11
Aug ’24US$3.73
US$7.27
+95.0%
30.5%US$10.00US$3.00n/a11
Jul ’24US$3.29
US$7.09
+115.5%
29.1%US$10.00US$3.00n/a11
Jun ’24US$3.54
US$7.00
+97.7%
29.8%US$10.00US$3.00n/a11
May ’24US$4.37
US$6.73
+53.9%
31.7%US$10.00US$3.00US$0.9111
Apr ’24US$3.18
US$6.80
+113.8%
30.7%US$10.00US$4.00US$1.2410
Mar ’24US$5.11
US$7.33
+43.5%
26.5%US$10.00US$4.00US$1.579
Feb ’24US$6.38
US$7.33
+14.9%
26.5%US$10.00US$4.00US$1.009
Jan ’24US$6.92
US$7.33
+6.0%
30.2%US$10.00US$3.00US$1.389
Dec ’23US$7.61
US$7.33
-3.6%
30.2%US$10.00US$3.00US$4.269
Nov ’23US$6.35
US$7.56
+19.0%
31.3%US$10.00US$3.00US$2.949
Oct ’23US$6.33
US$7.78
+22.9%
31.9%US$10.00US$3.00US$3.049
Sep ’23US$6.55
US$7.33
+12.0%
34.0%US$10.00US$3.00US$3.909
Aug ’23US$3.75
US$7.40
+97.3%
48.4%US$14.00US$2.00US$3.7310
Jul ’23US$4.28
US$7.33
+71.3%
51.4%US$14.00US$2.00US$3.299
Jun ’23US$2.97
US$7.33
+146.9%
51.4%US$14.00US$2.00US$3.549
May ’23US$3.63
US$7.89
+117.3%
42.0%US$14.00US$3.00US$4.379

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.